Ex­clu­sive: Au­toim­mune CAR-T biotech Kyver­na Ther­a­peu­tics is con­sid­er­ing an IPO next month

Kyver­na Ther­a­peu­tics, one of the clin­i­cal-stage biotechs at the fore­front of CAR-T cell ther­a­py’s ex­pan­sion in­to au­toim­mune dis­eases, is con­sid­er­ing an IPO as ear­ly as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER